Aurobindo Pharma plans to infuse around Rs 300 crore for biologics manufacturing facilities
The board approved entering into contract manufacturing operations (CMO) for biologicals for effective utilisation of capacities.
New Delhi: Drugmaker, Aurobindo Pharma has recently announced that its wholly-owned subsidiary, CuraTeQ Biologics, plans to invest around Rs 300 crore on capacity expansion of biologics manufacturing facilities.
The board of directors of CuraTeQ Biologics Pvt Ltd, at its meeting held on Thursday, approved the expansion of its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to the future requirements, Aurobindo Pharma said in a regulatory filing.
"The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore," the company said, adding that the facility is likely to be fully operational by FY26.
Further, the board also approved entering into contract manufacturing operations (CMO) for biologicals for effective utilisation of capacities.
Read also: Aurobindo Pharma arm bags USFDA okay for Triamcinolone Acetonide Injectable Suspension
This would augment the business prospects in this area as the global biologics contract manufacturing demand is growing at 8-10 per cent and CuraTeQ will actively seek customers in CMO area, the company added.
The company further said the board of its another wholly-owned subsidiary, Auro Vaccines Pvt Ltd, has also approved exploring possibilities to offer contract manufacturing service to global vaccine developers to effectively utilise its existing manufacturing capacity.
Auro Vaccines is engaged in the business of developing and manufacturing vaccines biologicals.
Read also: Aurobindo Pharma arm bags USFDA nod for Medroxyprogesterone Acetate Injectable Suspension
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.
The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA.
